$ORPH News

Last published 4y ago

4y agoINDO NINE ORPH PD+1Thinking about buying stock in Orphazyme, Indonesia Energy, Nine Energy, Pagerduty, or US Well Services?PR NewswireNEW YORK, March 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, INDO, NINE, PD, and USWS.
4y agoCYTR ORPHCytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type CBusiness WireNotes CytRx's Core Assets Are Unaffected by European Medicines Agency's Assessment of Arimoclomol Highlights Positive Developments Regarding Company's Core Assets, Including Aldoxorubicin CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"),
4y agoCYTR ORPHCytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type CBusiness WireOrphazyme Intends to Request a Type C Meeting in Q2 2022 Orphazyme Plans to Resubmit the NDA During H2 2022, Subject to FDA Discussions European Medicines Agency Opinion Expected in Q1 2022 CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Compan
4y agoBLDE CTXR DCFC ORPH+1Thinking about buying stock in Orphazyme, Yelp, Tritium DCFC, Blade Air Mobility, or Citius Pharmaceuticals?PR NewswireNEW YORK, Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, YELP, DCFC, BLDE, and CTXR.
5y agoCYTR IBRX ORPHCytRx Comments on Quarterly Results and Recent Strategic InitiativesBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the quarter ended Septem
5y agoCYTR ORPHCytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type CBusiness WireFDA Recommends Orphazyme Provides Supplemental Information and Analyses FDA Offers to have Further Interactions with Orphazyme to Identify Path to Resubmission for Arimoclomol in NPC CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a spe
5y agoCRXT JNJ ONCY ORPH+1Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming PeersPR NewswireVANCOUVER, BC, Oct. 14, 2021 /PRNewswire/ -- USA News Group - Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq doing even better with 14.7% and 12.1% gains respectively, th
5y agoADMP AZRX BPTH INDI+1Thinking about buying stock in Bio-Path Holdings, AzurRx BioPharma, Adamis Pharmaceuticals, indie Semiconductor, or Orphazyme?PR NewswireNEW YORK, Aug. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BPTH, AZRX, ADMP, INDI, and ORPH.
5y agoAXSM CASI ORPH TRIL+1Thinking about buying stock in Trillium Therapeutics, Vivos Therapeutics, Axsome Therapeutics, Orphazyme, or CASI Pharmaceuticals?PR NewswireNEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRIL, VVOS, AXSM, ORPH, and CASI.
5y agoCYTR IBRX ORPH PBLACytRx Comments on Quarterly Results and Recent Strategic InitiativesBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the second quarter ended
5y agoAAL FCEL GTIM ORPH+1Thinking about buying stock in Orphazyme, American Airlines, FuelCell Energy, PG&E Corp, or Good Times Restaurants?PR NewswireNEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, AAL, FCEL, PCG, and GTIM. To
5y agoCYTR DCTH IBRX LLY+2CytRx Announces Director Election Results from 2021 Annual Meeting of StockholdersBusiness WireNew Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative dise
5y agoCYTR IBRX ORPHCytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022Business WireImmunityBio's Receipt of U.S. Patent for Novel Immunotherapy, NANT Cancer Vaccine, Being Studied in Multiple Clinical Trials CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and de
5y agoCYTR IBRX ORPHCytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional InvestorBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced the closing of its previously announced sal
5y agoAAL F ORPH PLUG+1Thinking about buying stock in Ford, American Airlines, Plug Power, Orphazyme, or Snap?PR NewswireNEW YORK, July 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, AAL, PLUG, ORPH, and SNAP. To se
5y agoCYTR IBRX ORPHCytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional InvestorBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has entered into a securities purch
5y agoCYTR ORPHCytRx Comments on Orphazyme's Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type CBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") recently anno
5y agoMRIN ORPH PTN WISH+1Thinking about buying stock in ContextLogic, Orphazyme, Marin Software, Xpeng, or Palatin Technologies?PR NewswireNEW YORK, June 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, ORPH, MRIN, XPEV, and PTN. T
5y agoCAPR CTXR ORPH RCUS+1Thinking about buying stock in Arcus Biosciences, Capricor Therapeutics, Orphazyme, Sundial Growers, or Citius Pharmaceuticals?PR NewswireNEW YORK, June 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RCUS, CAPR, ORPH, SNDL, and CTXR. T
5y agoENTX IDRA NKLA ORPH+1Thinking about buying stock in Entera Bio, Torchlight Energy, Idera Pharmaceuticals, Nikola Corp, or Orphazyme?PR NewswireNEW YORK, June 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENTX, TRCH, IDRA, NKLA, and ORPH.
5y agoADIL CTXR GERN ORPH+1Thinking about buying stock in ContextLogic, Adial Pharmaceuticals, Geron Corp, Orphazyme, or Citius Pharmaceuticals?PR NewswireNEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, ADIL, GERN, ORPH, and CTXR. T
5y agoAMRN CLNE ORPH SENS+1Thinking about buying stock in Senseonics, Clean Energy Fuels, Orphazyme, Xpeng, or Amarin Corp?PR NewswireNEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SENS, CLNE, ORPH, XPEV, and AMRN.
5y agoCYTR ORPHCytRx Notes Orphazyme's Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type CBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") announced it has
5y agoATHA GERN ORPH TAL+1Thinking about buying stock in Geron Corp, Vaxart, Orphazyme, Athira Pharma, or TAL Education?PR NewswireNEW YORK, June 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GERN, VXRT, ORPH, ATHA, and TAL. To
5y agoACOR CLSD NNOX ORPH+1Thinking about buying stock in Clearside Biomedical, Acorda Therapeutics, Orphazyme, Nano-X Imaging, or Satsuma Pharmaceuticals?PR NewswireNEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, ACOR, ORPH, NNOX, and STSA. T
5y agoAVXL CRSR ORPH SENS+1Thinking about buying stock in Orphazyme, Corsair Gaming, Senseonics, Vaxart, or Anavex Life Sciences?PR NewswireNEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, CRSR, SENS, VXRT, and AVXL.
5y agoBB CLOV IRVRF ORPH+1Thinking about buying stock in Extended Stay America, Irving Resources, Clover Health, BlackBerry, or Orphazyme?PR NewswireNEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAY, IRV, CLOV, BB, and ORPH. To
5y agoCYTR IBRX ORPHCytRx Comments on Quarterly Results and Year-to-Date ProgressBusiness WireContinues Focusing on Near-Term Revenue Opportunities Linked to Orphazyme's Potential Regulatory Approvals for Arimoclomol in the Treatment of Niemann-Pick Disease Type C CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopha
5y agoCYTR ORPHCytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral SclerosisBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") announced that th
5y agoORPHCytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body MyositisBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (“IBM”) did not meet its prim ...
5y agoIBRX ORPHCytRx Comments on Fiscal Year 2020 Results and Highlights Strategic ProgressBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the fourth quarter and fiscal year ended December 31, 2020. In addition, CytRx highlighted developments pertaining to its licensing agreemen ...
5y agoORPHCytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type CBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") has released a new investor presentation that outlines its momentum ahead of potential U.S. and European approval of arimoclom ...
5y agoORPHCytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type CBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") has announced the appointment of Christophe Bourdon as its new Chief Executive Officer, effective as of April ...
5y agoORPHCytRx is Added to the LD Micro IndexBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it is now a part of the LD Micro Index (the “Index”).
5y agoNK ORPHCytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer PatientsBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) and ImmunityBio, Inc. (“ImmunityBio”) have announced that their ongoing Phase 2 clinical trials of a novel com ...
5y agoORPHCytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type CBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today provided an update on the U.S. Food and Drug Administration’s (“FDA”) review of Orphazyme A/S’s (NASDAQ: ORPH) (“Orphazyme”) New Drug Application (“NDA”) for arimoclomol ...
5y agoNK ORPHCytRx Comments on Proposed Combination of ImmunityBio and NantKwestBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated ImmunityBio, Inc. (“ImmunityBio”) and NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) on their proposed merger and announced plans to create a leading immunothe ...
5y agoORPHCytRx Announces Orphazyme’s U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type CBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical firm focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) has announced the expansion of its U.S. presence and workforce ahead of potential Food and Drug Administration ( ...
6y agoORPHCytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type CBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA) (NASDAQ:ORPH) (“Orphazyme”) has submitted a Marketing Authorisation Application (“MAA”) to the European Medicines Agency (“EMA”) f ...
6y agoORPHCytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for ArimoclomolBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) (“Orphazyme”) has announced new plans to accelerate commercial and other pre-launch activities during the fourth ...
6y agoORPHCytRx Issues Statement Regarding Orphazyme’s Global OfferingBusiness WireLOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) (“Orphazyme”) on the September 29, 2020 pricing of its global offering, consisting of an initial public offering of A ...